DocumentsDate added
Case Report
Bulegenova Minira G1*,Khairov Konstantin E2,Abdullaeva Gulgahan T3,Makhneva Anna F4
1 Professor, Head of Laboratory Department,Scientific Center of Pediatrics and Children Surgery, Al Farabi av, Kazakhstan
2 Executive Director, Surgery of Scientific Center of Pediatrics and Children’s Surgery, Al Farabi av, Kazakhstan
3 Head, Intensive Care Unit, Surgery of Scientific Center of Pediatrics and Children’s Surgery, Al Farabi av, Kazakhstan
4 Researcher, Laboratory of Pathomorphology, Surgery of Scientific Center of Pediatrics and Children’s Surgery, Al Farabi av, Kazakhstan
The name of the department(s) and institution(s) to which the work should be attributed:
Laboratory Department and Intensive Care Unit, Scientific Center of Pediatrics and Children Surgery
Address reprint requests to
*Minira Bulegenova,
Professor and Head of Laboratory Department, Scientific Center of Pediatrics and Children
Surgery, Al Farabi av., Kazakhstan
ABSTRACT
Blastopathy is a pathology that occurs during the blastula period, within the first 15 days from the moment of fertilization until embryo- and trophoblast ejection. Etiology of blastopathy is often unclear. This malformation is a variant of conjoined twins and occurs with a frequency of 1: 500,000 deliveries. Our article presents the clinical case of “Foetus in Fetu” in the practice of the Scientific Center of Pediatrics and Children Surgery, Almaty, Republic of Kazakhstan.
Newborn A was delivered from the perinatal centre on the 10th day of life. Prenatally, the ultrasound investigation of the foetus at the gestational age of 27–28 weeks diagnosed “pseudoomphalocele, ascites”. Mother was counseled by the geneticist on the recommended abortion, but she refused. At the age of 9 days the child was transferred to the Scientific Center of Pediatrics and Pediatric Surgery, where he was diagnosed as:congenital malformations, blastogenesis violation, asymmetric parasitic omphalopagus, foetus in fetu, congenital heart disease, interatrial septum defect (complete), globular heart, right-sided pneumonia, respiratory failure 1st stage, ischemic encephalopathy 2nd stage, prematurity 35–36 weeks and morphofunctional immaturity. The visible part of the parasitic foetus is presented with torso, pelvis, two lower limbs, vestigial appendage – the only “arthrogrypose” upper limb. On the basis of the clinical data, it was suggested that the parasitic foetus and the main foetus have a single blood circulatory system. A certain interest, in our opinion, was the study of changes in the homeostasis parameters of this patient, as the vital organs were single to both organisms.
KEYWORDS foetus in fetu, pseudoomphalocele, congenital malformations, internal homeostasis
REFERENCES
1. Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer. 2011;11(4):268–77.
2. Anup Mohta, Nita Khurana. Fetus-in-fetu or well-differentiatedteratoma-a continued controversy. Indian J Surg. 2011;73(5):372–4.
3. Chi JG, Lee YS, Park YS, Chang KY. Fetus-in-fetu: report of a case. Am J Clin Pathol. 1984;82(1):115–9.
4. Kuno N, Kadomatsu K, Nakamura M, Miwa-Fukuchi T,Hirabayashi N, Ishizuka T. Mature ovarian cystic teratoma with a highly differentiated homunculus: a case report. Birth Defects Res A Clin Mol Teratol. 2004;70(1):40–6.
5. Arlikar JD, Mane SB, Dhende NP, Sanghavi Y, Valand AG, Butale PR. Fetus in fetu: two case reports and review of literature. Pediatr Surg Int. 2009;25(3): 289–92.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents,and royalties through this collaborative research.All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.
Original article
Rajeev Kumar1,Swati Trivedi2,Mehta RK3,Jain Sunita4
1 Associate Professor, Department of Anaesthesia, Rama Medical College,Kanpur, India
2 Assistant Professor, Department of Anaesthesia, Rama Medical College,Kanpur, India
3 Professor & HOD Department of Anaesthesia, Rama Medical College,Kanpur, India
4 Professor, Department of Anaesthesia,Rama Medical College, Kanpur, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Anaesthesia, Rama Medical College, Kanpur, India
Address reprint requests to
*Dr. Rajeev Kumar, C-17, Newazad Nagar, Kalyanpur, Kanpur 208018, Uttar Pradesh
Article citation: Rajeev K, Trivedi S, Mehta RK, Sunita J. Effect of dexmedetomine on haemodynamics and isoflorane requirement during laparoscopic cholecystectomy. J Pharm Biomed Sci 2016;6(01):6–9. Available at www.jpbms.info
Abstract
Minimal access surgery like laparoscopic cholecystectomy has several advantages like less pain, early mobilisation, shorten stay in hospital and better cosmetic results. Due to the haemodynamic response to pneumoperitoneum, laparoscopic procedures are not free from risk. Uses of dexmedetomidine during general anaesthesia attenuate the haemodynamic response of pneumoperitoneum. In this study we evaluate the effect of dexmedetomidine on haemodynamic and the isoflorane requirement. A prospective randomised and double-blind study was conducted in 50 patients by dividing them in two groups. Group C as control (normal saline infusion) and Group D (dexmedetomine infusion) as test. Standard anaesthesia procedure is followed. During anaesthesia bispectral index (BIS) monitoring is done and it was maintained in the range of 40–60 with the titration in the dose of inhalational anaesthetic (isoflorane). Result shows that there is significant haemodynamic stability (P < 0.05) and 70% reduction in the requirement of isoflorane (P < 0.05) in Group D as compared to Group C. BIS was maintained in the range of 40–60. It is concluded that the use of Dexmedetomine results in better haemodynamic and requirement of inhalational anaesthetic can be reduced.
KEYWORDS dexmedetomine, laparoscopic cholecystectomy, BIS, anaesthesia
REFERENCES
1.Joris JL, Noirot DP, Legrand MJ, Jacquet NJ, Lamy ML. Hemodynamic changes during laparoscopic cholecystectomy. Anesth Analg. 1993;76:1067–71.
2.Wilcox S, Vandam LD. Alas, poor Trendelenburg and his position! A critique of its uses and effectiveness. Anesth Analg. 1988;67:574–8.
3.Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000;90:699–705.
4.Carollo DS, Nossaman BD, Ramadhyani U. Dexmedetomidine:a review of clinical applications. Curr Opin Anaesthesiol. 2008;21:457–61.
5.Scheinin B, Lindgren L, Randell T, Scheinin H, Scheinin M.Dexmedetomidine attenuates sympathoadrenal responses to tracheal intubation and reduces the need for thiopentone and peroperative fentanyl. Br J Anaesth. 1992;68:126–31.
6.Aho M, Erkola O, Kallio A, Scheinin H, Korttila K. Dexmedetomidine infusion for maintenance of anesthesia in patients undergoing abdominal hysterectomy. Anesth Analg. 1992;75:940–6.
7.Jaakola ML, Ali-Melkkilä T, Kanto J, Kallio A, Scheinin H,Scheinin M. Dexmedetomidine reduces intraocular pressure,intubation responses and anaesthetic requirements in patients undergoing ophthalmic surgery. Br J Anaesth. 1992;68:570–5.
8.Monitoring Level of Consciousness during anesthesia & sedation: A Clinicians Guide to the Bispectral Index By Scott D. Kelley.
9.Punjasawadwong Y, Phongchiewboon A, Bunchungmongkol N. Bispectral index for improving anaesthetic delivery and postoperative recovery. Cochrane Database Syst Rev.2007;(4):CD003843.
10.Song D, Girish PJ, White PF. Titration of volatile anaesthetics using bispectral index facilitates recovery after ambulatory anaesthesia. Anesthesiology. 1997;87:842–8.
11.Katoh T, Bito H, Sato S. Influence of age on hypnotic requirement, bispectral index and 95% spectral edge frequency associated with sedation induced by sevoflurane. Anesthesiology. 2000;92:55–61.
12.Gurman GM, Popescu M, Weksler N, Steiner O, Avinoah E, Porath A. Influence of the cortical electrical activity level during general anaesthesia on the severity of immediate postoperative pain in the morbidly obese. Acta Anaesthesiol Scand. 2003;47:804–8.
13.Henneberg SW, Rosenberg D, Jensen EW, Ahn P, Burgdorff B, Thomsen LL. Perioperative depth of anaesthesia may influence postoperative opioid requirements. Acta Anaesthesiol Scand. 2005;49:293–6.
14.Avidan MS, Zhang L, Burnside BA, Finkel KJ, Searleman AC, Selvidge, BS, et al. Anaesthesia awareness and the bispectral index. N Engl J Med. 2008;358:1097–108.
15.Farag E, Chelune GJ, Schubert A, Mascha EJ. Is depth of anesthesia, as assessed by the bispectral index, related to postoperative cognitive dysfunction and recovery? Anesth Analg. 2006;103:633–40.
16.Talke P, Lobo E, Brown R. Systemically administered alpha2- agonist-induced peripheral vasoconstriction in humans. Anesthesiology. 2003;99:65–70.
17.Piascik MT, Soltis EE, Piascik MM, Macmillan LB. Alphaadrenoceptors and vascular regulation: molecular, pharmacologic and clinical correlates. Pharmacol Ther. 1996;72:215–41.
18.Correa-Sales C, Rabin BC, Maze M. A hypnotic response to dexmedetomidine, an alpha 2 agonist, is mediated in the locus coeruleus in rats. Anesthesiology. 1992;76:948–52.
19.Nacif-Coelho C, Correa-Sales C, Chang LL, Maze M. Perturbation of ion conductance alters the hypnotic response to the alpha sub 2-adrenergic agonist dexmedetomidine in the locus coeruleus in rats. Anesthesiology. 1994;81:1527–34.
20.Vickery RG, Sheridan BC, Segal IS, Maze M. Anesthetic and hemodynamic effects of the stereoisomers of medetomidine, an alpha-2-adrenergic agonist, in halothane anesthetized dogs. Anesth Analg. 1988;67:611–15.
21.Aho M, Lehtinen AM, Erkola O, Kallio A, Korttila K. The effect of intravenously administered dexmedetomidine on perioperative hemodynamics and isoflurane requirements in patients undergoing abdominal hysterectomy. Anesthesiology. 1991;74:997–1002.
22.Neogi M, Basak S, Ghosh D, Mukherjee S, Dawn S, Bhattacharjee DP. A randomized double-blind placebo-controlled clinical study on the effects of gabapentin premedication on hemodynamic stability during laparoscopic cholecystectomy. J Anaesthesiol Clin Pharmacol. 2012;28:456–9.
23.Keniya VM, Ladi S, Naphade R. Dexmedetomidine attenuates sympathoadrenal response to tracheal intubation and reduces perioperative anesthetic requirement. Indian J Anesth. 2011;55:352–7.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents,and royalties through this collaborative research.All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.
REVIEW ARTICLE
Mitul Mishra1*,Prachi Mishra2,Vaibhao Shambharkar3,Amber Raut4
1 Assistant Professor, SDKS Dental College & Hospital, Hingna, Nagpur, India
2 Private Practitioner, Nagpur, India
3 Assisant Professor, SDKS Dental College & Hospital, Nagpur, India
4 Assistant Professor, SDKS Dental College & Hospital, Hingna, Nagpur, India
Address reprint requests to
*Dr. Mitul K Mishra,
Department of Periodontics, SDKS Dental College and Hospital, Hingna, Nagpur, India
Article citation: Mishra M, Mishra P, Shambharkar V, Raut A. Scaffolds in periodontal regeneration. J Pharm Biomed Sci 2016;06(01):10–17.
Available at www.jpbms.info
ABSTRACT
Periodontal tissue engineering requires triad of cells, inductive component and a scaffold on
which growth can occur. Previously periodontal treatment was aimed to selectively repopulate the defect site with cell that has capability to regenerate lost tissue by using the
concept of guided tissue regeneration. However, this technique is not always possible. Use of scaffolds that can also deliver cells required for regeneration to occur is relatively a newer concept. A biomaterial is defined as a nonviable material used in a medical device, intended
to interact with biological systems. For a device to be effective, it has to meet certain criteria
based on organ and tissue properties and specific goals. Every material available in market has its own advantages and disadvantages. This review will mainly focus on the devices along with the advancement taking place related to cell delivery system.
KEYWORDS regeneration, tissue engineering, scaffold, cell delivery system.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents,and royalties through this collaborative research.
All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.
Case Report
Sanjeev Kumar Salaria1,Navjot Kaur Chahal2*,Surinder S Chahal3,Prabhdiljit Singh4
1 Head of Department, Department of Periodontology and Oral Implantology,Surendera Dental College and Research Institute, Sri Ganganagar, Rajasthan, India
2* Post graduate student, Department of Periodontology and Oral Implantology,Surendera Dental College and Research Institute, Sri Ganganagar, Rajasthan, India
3 Post graduate student, Department of Conservative Dentistry & Endodontics,Surendera Dental College and Research Institute, Sri Ganganagar, Rajasthan, India
4 Intern, Surendera Dental College and Research Institute, Sri Ganganagar, Rajasthan, India
Address reprint requests to
*Dr. Navjot Kaur Chahal,
Post graduate student, Department of Periodontology and Oral Implantology, Surendera Dental College and Research Institute, Sri Ganganagar,Rajasthan, India
Article citation: Salaria SK, Chahal NK, Chahal SS, Singh P. Single flap approach with lingual access in conjugation with PRF and Biograft HABG for the management of residual grade II furcation defect occurring from primary endodontic with secondary periodontal lesion:an interdisciplinary case report. J Pharm Biomed Sci 2016;06(01):18–22. Available at www.jpbms.info
ABSTRACT
The success of an endodontic and periodontal lesion depends on the elimination of both of these disease processes; as the endodontic therapy results in healing of the endodontic component of involvement while the prognosis or outcome of tooth would finally depend on the healing of the periodontal structures. In this case report, a residual grade II furcation defect of primary endodontic with secondary periodontal lesion was managed by endodontic therapy followed by periodontal regenerative therapy with BioGraft® hydroxy apatite active bone graft (HAGB) and platelet rich fibrin (PRF) utilizing single flap access technique. At 6 months post operatively there was reduction in periodontal pocket and gain in clinical attachment level with complete regeneration in grade II furcation bone defect was observed without any post operative complication.
KEYWORDS endo-perio lesion, residual grade II furcation, root canal therapy, periodontal regeneration, single flap access.
REFERENCES
1.Simring M, Goldberg M. The pulpal pocket approach: retrograde periodontitis. J Periodontol 1964;35:22–48.
2.Chen SY, Wang HL, Glickman GN. The influence of endodontic treatment upon periodontal wound healing. J Clin Periodontol. 1997;24(7):449–56.
3.Newman T, Klokkevold, Carranza FA. Clinical Periodontology, 10th ed. Philadelphia: Saunders; 2006.
4.Trombelli L, Farina R, Franceschetti G, Calura G. single flap approach with buccal access in periodontal reconstructive procedures. J Periodontol. 2009;80:353–60.
5.Deodhar AK, Rana RE. Surgical ph ysiology of wound healing: a review. J Postgrad Med. 1997;43:52–6.
6.Giannobile WV. Periodontal tissue engineering by growth factors. Bone. 1996;19(Suppl 1):23S–37S.
7.Diss A, Dohan DM, Mouhyi J, Mahler P. Osteotome sinus floor elevation using Choukroun’s platelet rich fibrin as grafting material: a1-year prospective pilot study with microthreaded implants. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105:572e 9.
8.Tsai CH, Shen SY, Zhao JH, Chang YC. Platelet rich fibrin modulates cell proliferation of human periodontal related cells in vitro reports. J Dent Sci. 2009;4:130e5.
9.Debnath T, Chakraborty A, Pal TK. Aclinical study on the efficacy of hyhroxyapatite-bioactive composite granules in the management of periodontal bony defects. J Indian Soc Periodontol. 2014;18(5):593–600.
10.Sharma A, Pradeep AR. Autologous Platelet rich fibrin in the treatment of mandibular degree II furcation defects: a randomized clinical trial. J Periodontol. 2011;82:1396–403.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents,and royalties through this collaborative research.
All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the
official policy or position of the Department of Defense.
Original article
Aijun Zhang, Pengfei Fu, Zaijun Zhang, Haiyun Chen, Pei Yu*
Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardiocerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou 510632, China
Address reprint requests to
*Prof Pei Yu,
Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardio-cerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou 510632 China
The name of the department(s) and institution(s) to which the work should be attributed:
Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardiocerebrovascular Diseases, Jinan University College of Pharmacy
Article citation: Zhang A, Fu P, Zhang Z, Chen H, Yu P. Design, synthesis and evaluation of novel chloro-oxime derivatives for neurodegenerative diseases. J Pharm Biomed Sci 2016;06(01):31–38.
Available at www.jpbms.info
ABSTRACT
Neurodegenerative disease is a fatal disease of the human nervous system, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis and related polyglutamine expansion diseases. The US FDA had approved several drugs to treat neurodegenerative diseases, however, almost none of them could delay progress of these diseases and offer cure. A key molecular pathway implicated in neurodegenerative diseases is the misfolding aggregation and accumulation of proteins in neurons. Chloro-oxime derivatives, such as bimoclomol and arimoclomol, promote the expression of heat shock proteins and improve the abilities of normal protein folding and degrade misfolded proteins. Based on the structure of bimoclomol and arimoclomol,we substituted the pyridine and piperazine by TMP and other amino groups, and synthesised a series of novel chloro-oxime derivatives. Among these chloro-oxime derivatives, compounds 9b and 13b were demonstrated to be neuroprotective against MG-132-induced neurotoxicity in SH-SY5Y cells.
KEYWORDS chloro-oxime derivatives, molecule chaperone amplifiers, misfolding protein, neurodegenerative diseases.
REFERENCES
1.Nagai Y, Fujikake N, Popiel HA, Wada K. Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases. Curr Pharm Biotechnol. 2010;11(2):188–97.
2.Pehlivan SB. Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases. Pharmaceut Res. 2013;30(10):2499–511.
3.Fisher A. Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer’s disease. J Neurochem. 2012;120(Suppl 1):22–33.
4.Poon LH, Kang GA, Lee AJ. Role of tetrabenazine for Huntington’s disease-associated chorea. Ann Pharmacother 2010;44(6):1080–9.
5.Traynor BJ, Bruijn L, Conwit R, Beal F, O’Neill G, Fagan SC, Cudkowicz ME. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology. 2006;67(1):20–7.
6.Agorogiannis EI, Agorogiannis GI, Papadimitriou A, Hadjigeorgiou GM. Protein misfolding in neurodegenerative diseases. Neuropathol Appl Neurobiol. 2004;30(3):215–24.
7.Gavrin LK, Denny RA, Saiah E. Small molecules that target protein misfolding. J Med Chem. 2012;55(24):10823–43.
8.Muchowski PJ, Wacker JL. Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci. 2005;6(1): 11–22.
9.Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839–40.
10.Kalmar B, Kieran D, Greensmith L. Molecular chaperones as therapeutic targets in amyotrophic lateral sclerosis. Biochem Soc Trans. 2005;33(Pt 4):551–2.
11.Soti C, Nagy E, Giricz Z, Vigh L, Csermely P, Ferdinandy P. Heat shock proteins as emerging therapeutic targets. Br J Pharmacol. 2005;146(6):769–80.
12.Westerheide SD, Morimoto RI. Heat shock response modulators as therapeutic tools for diseases of protein conformation. J Biol Chem. 2005;280(39):33097–100.
13.Zhang Z, Wei T, Hou J, Li G, Yu S, Xin W. Tetramethylpyrazine scavenges superoxide anion and decreases nitric oxide production in human polymorphonuclear leukocytes. Life Sci. 2003;72(22):2465–72.
14.Liu X, Zhang R, Xu W, Li C, Zhao Q, Wang X. Synthesis of the novel liqustrazine derivatives and their protective effect on injured vascular endothelial cell damaged by hydrogen peroxide. Bioorg Med Chem Lett. 2003;13(13):2123–6.
15.Sun Y, Jiang J, Zhang Z, Yu P, Wang L, Xu C, Liu W,Wang Y. Antioxidative and thrombolytic TMP nitrone for treatment of ischemic stroke. Bioorg Med Chem. 2008;16(19): 8868–74.
16.Zhou Y, Vu K, Chen Y, Pham J, Brady T, Liu G, et al. Chloro-oxime derivatives as novel small molecule chaperone amplifiers. Bioorg Med Chem Lett. 2009;19(11):3128–35.
17.Henkel JG, Hane JT, Gianutsos G. Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution. J Med Chem. 1982;25(1):51–6.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Acknowledgements: This work was supported partially by The Natural Science Foundation of Guangdong Province(2014A030320174).
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.